QRG Capital Management Inc. Buys 569 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

QRG Capital Management Inc. raised its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report) by 3.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 18,279 shares of the company’s stock after purchasing an additional 569 shares during the period. QRG Capital Management Inc.’s holdings in Neurocrine Biosciences were worth $2,106,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of NBIX. Norden Group LLC bought a new stake in Neurocrine Biosciences during the first quarter valued at approximately $393,000. Janney Montgomery Scott LLC lifted its holdings in shares of Neurocrine Biosciences by 3.1% in the 1st quarter. Janney Montgomery Scott LLC now owns 8,907 shares of the company’s stock worth $1,228,000 after acquiring an additional 270 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in shares of Neurocrine Biosciences by 32.5% in the 1st quarter. Daiwa Securities Group Inc. now owns 8,590 shares of the company’s stock worth $1,185,000 after acquiring an additional 2,109 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of Neurocrine Biosciences by 33.4% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 4,937 shares of the company’s stock worth $681,000 after acquiring an additional 1,235 shares during the last quarter. Finally, Forsta AP Fonden lifted its holdings in shares of Neurocrine Biosciences by 94.3% in the 1st quarter. Forsta AP Fonden now owns 34,200 shares of the company’s stock worth $4,717,000 after acquiring an additional 16,600 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Trading Down 1.1 %

Neurocrine Biosciences stock opened at $123.98 on Friday. The firm has a 50 day moving average of $118.45 and a 200 day moving average of $133.21. The firm has a market capitalization of $12.55 billion, a price-to-earnings ratio of 33.24 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 12-month low of $103.63 and a 12-month high of $157.98.

Analysts Set New Price Targets

Several brokerages recently commented on NBIX. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research note on Thursday, October 17th. Barclays reduced their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Citigroup boosted their price objective on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the company a “neutral” rating in a research report on Friday, August 2nd. Morgan Stanley boosted their price objective on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 12th. Finally, Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Five investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $163.91.

View Our Latest Research Report on Neurocrine Biosciences

Insider Buying and Selling

In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Neurocrine Biosciences news, Director William H. Rastetter sold 14,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the sale, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at approximately $4,741,180.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,063 shares of company stock valued at $7,023,330. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Profile

(Free Report)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Further Reading

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIXFree Report).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.